Study of Erythropoietin in Newborns and Children (EPO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03957863|
Recruitment Status : Recruiting
First Posted : May 21, 2019
Last Update Posted : May 21, 2019
Erythropoietin (EPO) is a glycoprotein hormone with a molecular weight of 30.4 kDa, responsible for regulating erythropoiesis in adults, newborns and fetuses. During pregnancy, the concentration of maternal serum EPO increases linearly to allow for effective erythropoiesis over time. In the fetus, in the first 30 weeks of gestation, the liver is the main synthetic organ. Thereafter, there is a progressive transfer of the synthesis of EPO to the kidneys. In the long term, under normal conditions of oxygenation, the fetal synthesis of EPO is mainly ensured by the kidney.
Because of the impossibility of making EPO tissue reserves and the inability of EPO to pass the placental barrier, the concentration of circulating EPO in the fetus reflects the balance between production and elimination. During the last trimester of pregnancy, in the absence of patent hypoxia, fetal concentrations of circulating EPO are between 10 and 50 mIU /ml, while in amniotic fluid the EPO is found at lower concentrations, between 2 and 20 mIU /ml.
In adults, EPO synthesis is primarily renal, and incidentally hepatic, even if in certain pathological situations (end-stage kidney disease or polycystosis) the liver is able to take over and synthesize EPO with an electrophoretic profile similar to that of the EPO from the umbilical cord, but often in insufficient quantities.
The objective of this study is to describe the forms of EPO in newborns and to compare possible iso-forms with those of adults.
|Condition or disease||Intervention/treatment|
|Newborn Infant Child Under One Year of Age||Biological: Plasma collection for EPO assay|
|Study Type :||Observational|
|Estimated Enrollment :||40 participants|
|Official Title:||Study of Erythropoietin in Newborns and Children|
|Actual Study Start Date :||March 12, 2019|
|Estimated Primary Completion Date :||March 2020|
|Estimated Study Completion Date :||March 2020|
- Biological: Plasma collection for EPO assay
Plasma collection for EPO assay
- EPO concentration UI/L [ Time Frame: Baseline ]
- Electrophoretic profile of EPO [ Time Frame: Baseline ]It is an indicator of glycosylation differences (more complex forms including sialic acids are more acidic, less complex forms are more basic)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03957863
|Contact: François Girodon||03.80.29.30.47 ext +email@example.com|
|Chu Dijon Bourogne||Recruiting|
|Dijon, France, 21000|
|Contact: François Girodon 03.80.29.30.47 ext +33 firstname.lastname@example.org|